Streetbeat News

Stock Prices

ASND

BMRN

BioMarin Pharmaceutical Inc. reported strong Q3 results with EPS and sales beating expectations. However, William Blair downgraded the stock, citing skepticism about future growth from its clinical pipeline. Despite strong sales from Voxzogo, competition from Ascendis Pharma's new product poses a threat. Analysts have mixed reactions, with some lowering price targets.

Portfolio Pulse from Vandana Singh

October 30, 2024 | 6:42 pm

TXG

10x Genomics (NASDAQ:TXG) reported a Q3 loss of 30 cents per share, better than expected, but missed sales estimates. The company lowered its FY24 revenue guidance due to sales restructuring and cautious customer spending. Analysts adjusted their price targets, with UBS, JP Morgan, and Goldman Sachs lowering them, while Citigroup maintained a Buy rating.

Portfolio Pulse from Avi Kapoor

October 30, 2024 | 6:41 pm

SNAP

Snap Inc (NYSE:SNAP) shares surged after reporting better-than-expected Q3 earnings, driven by cost management and direct response ad growth. Analysts remain cautious due to challenges in brand revenue and uncertainties in future growth.

Portfolio Pulse from Priya Nigam

October 30, 2024 | 6:39 pm

QRVO

Qorvo, Inc. (NASDAQ:QRVO) stock is experiencing a significant decline after reporting Q2 results that beat estimates but issuing Q3 guidance below expectations. The company anticipates challenges in the smartphone market and plans cost-cutting measures. Analysts have adjusted their ratings and price targets, contributing to the stock's 26.1% drop.

Portfolio Pulse from Dylan Berman

October 30, 2024 | 6:37 pm

CB

Chubb (NYSE:CB) reported stronger-than-expected Q3 earnings, with EPS of $5.72 beating the $4.98 estimate, but sales of $12.28 billion missing the $12.54 billion estimate. Despite the positive earnings, shares fell 1.2%. Analysts raised price targets, reflecting optimism.

Portfolio Pulse from Avi Kapoor

October 30, 2024 | 6:32 pm

SRDX

Surmodics, Inc. announced promising early results from a subset analysis of 60 patients with limb ischemia, showing a 96.8% success rate in procedural flow restoration using the Pounce System. The results were presented at the 36th Annual TCT Symposium.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:31 pm

BMY

GILD

LYEL

NVS

Lyell Immunopharma (NASDAQ:LYEL) has been downgraded by BofA Securities from Buy to Underperform, with a price target reduced from $6 to $1. This follows Lyell's acquisition of ImmPACT Bio and the discontinuation of several programs to focus on its CAR T-cell clinical programs. The acquisition introduces complexities and potential distractions, with competition from established players like Gilead Sciences, Bristol Myers Squibb, and Novartis.

Portfolio Pulse from Vandana Singh

October 30, 2024 | 6:31 pm

URI

United Rentals (NYSE:URI) has significantly outperformed the market over the past 5 years, with an annualized return of 41.05%. A $100 investment in URI 5 years ago would now be worth $559.33, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 30, 2024 | 6:30 pm

TRV

Travelers Companies (NYSE:TRV) has outperformed the market over the past 20 years with an average annual return of 10.09%. A $100 investment in TRV 20 years ago would be worth $688.79 today. The article highlights the impact of compounded returns over time.

Portfolio Pulse from Benzinga Insights

October 30, 2024 | 6:30 pm

BTCUSD

Bitwise CIO Matt Hougan predicts Bitcoin could surpass $100,000 by 2025, driven by institutional adoption and ETF inflows. He highlights Bitcoin's lighter regulatory burden and its role as a hedge against inflation. Hougan expects new all-time highs this year, with institutional involvement and fixed supply dynamics as key drivers.

Portfolio Pulse from Murtuza Merchant

October 30, 2024 | 6:29 pm